神経膠腫におけるMIB-1陽性率と臨床像および生命予後との関連

概要

論文の詳細を見る
The treatment and prognosis of patients with astrocytic tumors are currently guided by histopathological classification. Histological differentiation is, however, not clear in some tumors. The aim of this study is to evaluate immunohistochemically using the antibody, MIB-1 as a prognostic indicator for patients with astrocytic tumors. We examined 35 astrocytic tumors of patients for whom clinical indices were well documented. There were 15 glioblastomas, 13 anaplastic astrocytomas, 5 astrocytomas and 2 pilocytic astrocytomas. The formalin-fixed, paraffin-embedded archival tissue sections of 35 cases were immunostained using monoclonal antibody MIB-1. The MIB-1 staining index (MIB-1 SI) was defined as the number of MIB-1 positive cells divided by the total number of tumor cells in most viable fields on the slice. The MIB-1 SI of 35 cases ranged from 0.6 to 39.6% (median: 15.6%), which were well correlated with the malignancy of histological classification of WHO (p < 0.05, Kruskal-Wallis test). The clinical survival time of the patients was also correlated with MIB-1 SI (p = -0.89, p< 0.05, Spearman rank correlation test). Thus, patients with less than 16% of MIB-1 SI had better prognosis in the survival time than those with more than 16% (p < 0.05, log rank test). We consider MIB-1 SI using archival paraffin-embedded samples as a valuable prognostic indicator in astrocytic tumors.
東京女子医科大学の論文
1997-06-25